Étiquette : traitements

Negative experiences of patients using medicinal cannabis : A systematic review of qualitative studies, Or Gliksberg et al., 2023

Negative experiences of patients using medicinal cannabis : A systematic review of qualitative studies Or Gliksberg, P Talma Kushnir,  Sharon R. Sznitman, Shaul Lev-Ran, Silviu Brill, Ben H. Amit, Daniel Feingold PhD, Journal of Clinical Nursing, 2023, 1-12. doi : 10.1111/jocn.16653 Abstract Aims and Objectives : In this study, we systematically reviewed qualitative studies concerning patients' experience with medicinal cannabis (MC) use, to gain insight into the negative effects of MC. Background : Over the past decades, the use of MC for therapeutic purposes has increased. However, there is conflicting and insufficient data on possible negative physiological and psychological effects of MC treatment. Design : A systematic review was [...]

Lire la suite

Cannabis and Depression, Daniel Feingold & Aviv Weinstein, 2021

Cannabis and Depression Daniel Feingold, Aviv Weinstein Advances in Experimental medicine and Biology, 2021, 1264, 67-80. In book : "Cannabinoids and Neuropsychiatric Disorders", Aviv Weinstein 's Lab Doi : 10.1007/978-3-030-57369-0_5 Abstract There is a growing body of evidence pointing to the co-occurrence of cannabis use and depression. There is also some evidence that the use of cannabis may lead to the onset of depression; however, strong evidence points to the inverse association; i.e. that depression may lead to the onset or increase in cannabis use frequency. Observational and epidemiological studies have not indicated a positive long-term effect of cannabis use on the course and outcome of [...]

Lire la suite

Attitudes Toward the Use of Medical Cannabis and the Perceived Efficacy, Side-effects and Risks : A Survey of Patients, Nurses and Physicians, Neta HaGani et al., 2021

Attitudes Toward the Use of Medical Cannabis and the Perceived Efficacy, Side-effects and Risks : A Survey of Patients, Nurses and Physicians Neta HaGani, Sharon Sznitman, Michael Dor, Gil Bar-Sela, Dana Oren, Lilia Margolis-Dorfman, Itay Goor-Aryeh & Manfred S. Green Journal of Psychoactive Drugs, 2021, 1-10. Doi : 10.1080/02791072.2021.2009598   ABSTRACT Gaps between physician and patient perceptions may lead to misunderstandings and mismanage of treatment. There are sparse data about the differences in opinions toward medical cannabis (MC) between patients and health professionals. The aim of this study was to examine the attitudes toward MC, its perceived efficacy, side effects and risk of dependency, among patients, [...]

Lire la suite

Increased cannabis intake during the COVID-19 pandemic is associated with worsening of depression symptoms in people with PTSD, Murkar et al., 2022

Increased cannabis intake during the COVID-19 pandemic is associated with worsening of depression symptoms in people with PTSD A. Murkar, T. Kendzerska, J. Shlik, L. Quilty, M. Saad and R. Robillard BMC Psychiatry, 2022, 22, 554 Doi : 10.1186/s12888-022-04185-7   Abstract Background: Some evidence suggests substance use affects clinical outcomes in people with posttraumatic stress disorder (PTSD). However, more work is required to examine links between mental health and cannabis use in PTSD during exposure to external stressors such as the COVID-19 pandemic. This study assessed mental health factors in individuals with self-reported PTSD to: (a) determine whether stress, anxiety, and depression symptoms were associ- ated with changes [...]

Lire la suite

The Rapid Rise in Investment in Psychedelics— Cart Before the Horse, Joshua PHELPS et al., 2022

The Rapid Rise in Investment in Psychedelics— Cart Before the Horse Joshua PHELPS, Ravi N. SHAH, Jeffrey A. LIEBERMAN, JAMA Psychiatry, 2022, 79, (3), 189-190. Doi : 10.1001/jamapsychiatry.2021.3972   Anticipating a renaissance, many psychedelic medicine companies have conducted initial public offerings, where in private companies first issue news hares of stock for sale to the public, making the companies publicly traded entities.1 As of this writing, there are more than 50 publicly traded companies related to the development or administration of psychedelic like drugs in the US, with at least 3 valued at more than $1 billion. The market for psychedelic substances is projected to [...]

Lire la suite

Conducting Qualitative Research With Psychedelic Psychopharmacologists : Challenges of Co-Production in an Era of Interdisciplinarity, Tehseen Noorani, 2017

Conducting Qualitative Research With Psychedelic Psychopharmacologists : Challenges of Co-Production in an Era of Interdisciplinarity Tehseen Noorani SAGE Research Methods Cases Part 2,  March 3, 2017, 1-14 Doi : 10.4135/9781526404862   Abstract From 2013 to 2015, I worked as a postdoctoral research fellow with a team of pharmacologists experimenting with psilocybin, an illegal psychoactive compound found in psychedelic mushrooms. The team had conducted an open-label clinical trial with long-term cigarette smokers, using psilocybin-assisted psychotherapy to help them quit. The smoking outcomes were very promising, occurring alongside many other profound positive life-changes. The team wanted to investigate further the mechanisms of change by which the study led [...]

Lire la suite

Psychedelic science in post-COVID-19 psychiatry, J. R. Kelly et al., 2020

Psychedelic science in post-COVID-19 psychiatry J. R. Kelly, M. T. Crockett, L. Alexander, M. Haran, A. Baker, L. Burke, C. Brennan and V. O’Keane Irish Journal of Psychological Medicine, 2020, 1-6. doi:10.1017/ipm.2020.94   The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are pre- dicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and maladaptive habitual patterns of cognition [...]

Lire la suite

Effectiveness of Psilocybin on Depression : A Qualitative Study, Redhwan Ahmed Al-Naggar et al., 2021

Effectiveness of Psilocybin on Depression : A Qualitative Study Redhwan Ahmed Al-Naggar, Hisham Alshaikhli, Gwen Erlam Electronic Journal of General Medicine, 2021, 18, (3), em296. doi : 10.29333/ejgm/10862   ABSTRACT Introduction : Psilocybin mushroom use is well documented in spiritual and religious ceremonies globally. This drug is now the most popular in Europe and the USA. Objective : The objective of this study is to explore the experiences and effects of psilocybin on patients with depression and anxiety. Method : A qualitative study was conducted interviewing ten participants currently taking psilocybin while experiencing depression and/or anxiety. Ethical approval was obtained from the University ethics committee. Participants were recruited [...]

Lire la suite